RxDoctor Payments Data

Vicki Raab, MD

Neurology · Ocean, NJNPI 1073600748

Payments from drug & device makers

$25,600in general payments, 2019–2025

Across 439 payments — averaging $58.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$23K
  • Novartis$884
  • Pfizer$795
  • Biohaven Pharmaceutical Holding Company Ltd.$174
  • Biohaven Pharmaceuticals, Inc.$151
  • Alphatec Spine, Inc$144
  • plus $725 from 17 others

What the payments were for

  • Speaking & faculty fees$20,87582%
  • Food & beverage$4,61218%
  • Education$110%
  • Other$1020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,600 in reported general payments places this provider in the 75th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$119,525
Medicare patients
590
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a12$95,580
QuliptaAtogepant43$44,989
UbrelvyUbrogepant30$35,159
Nurtec OdtRimegepant Sulfate21$34,187
FingolimodFingolimod Hcl22$11,695
HorizantGabapentin Enacarbil14$9,663
Dalfampridine ErDalfampridine19$9,628
Lamotrigine ErLamotrigine15$7,946
Memantine Hcl133$6,458
Carbidopa-LevodopaCarbidopa/Levodopa176$5,562
DilantinPhenytoin Sodium Extended17$3,663
KlonopinClonazepam12$3,637
Donepezil Hcl218$3,463
Gabapentin154$3,242
Dimethyl Fumarate18$2,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$22,728$80,14873 claims
PfizerNurtec Odt, Dilantin$795$37,85038 claims
Upsher-smith Laboratories LLCTopiramate$79$1,93699 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 521 neurology providers in New Jersey.

Other neurology in Ocean

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →